Investing.com - Harrow Health (NASDAQ: HROW) reported second quarter EPS of $-0.020, $0.02 better than the analyst estimate of $-0.040. Revenue for the quarter came in at $33.5M...
Investing.com - Harrow Health (NASDAQ: HROW) reported first quarter EPS of $-0.030, in line with the analyst estimate of $-0.030. Revenue for the quarter came in at $26.1M versus...
Investing.com - Harrow Health (NASDAQ: HROW) reported first quarter EPS of $0.070, $0.19 better than the analyst estimate of $-0.120. Revenue for the quarter came in at $20.3M...
By Davit Kirakosyan Macquarie lowered the price target on Walt Disney (NYSE:DIS) to $110.00 from $120.00 while maintaining an Outperform rating. The analysts modestly reduced...
Harrow Health (HROW) reported Q3 EPS of ($0.24), $0.23 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $22.8 million versus the consensus estimate of...
Investing.com - Harrow Health (NASDAQ:HROW) reported on Monday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations. Harrow Health...
Harrow Health (NASDAQ:HROW) reported Q2 EPS of $0.01, $0.03 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $23.3 million versus the consensus...
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced that effective today, it has changed its corporate name from “Harrow Health, Inc.” to “Harrow, Inc.”...
Harrow (HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Application (NDA) for VIGAMOX® (moxifloxacin...
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it priced an underwritten registered public offering of 3,380,282 shares of its common...
Corporate Insiders Bought Shares Worth $660.4K in the Last 3 Months. Since these last inside trades, the stock price opened at $7.32 on 7.21 and closed at $8.26 on 7.23 an 13% increase.